Douglas Mental Health University Institute and Department of Psychiatry, McGill University, Montréal, Canada.
Early Interv Psychiatry. 2010 May;4(2):189-95. doi: 10.1111/j.1751-7893.2010.00174.x.
Medication adherence is a determining factor for symptomatic remission and relapse prevention following a first episode of psychosis (FEP). Neurocognitive abilities have received only scant attention so far as a risk factor for poor adherence but significant impairments with memory and/or planning abilities could play a role. We examined early medication adherence following admission to a specialized clinical programme for FEP.
One hundred sixty FEP participants and 35 healthy controls completed an exhaustive neurocognitive assessment. FEP participants were categorized as a function of their medication adherence at 6 months into poor (n = 34), partial (n = 27) and full (n = 99) adherence, respectively. Domain-specific and global measures of cognitive ability were examined.
No measure of neurocognition could significantly discriminate amongst the three medication adherence groups.
These results suggest no strong associations between neurocognitive abilities and medication adherence in first episode of psychosis.
药物依从性是首发精神病（FEP）症状缓解和预防复发的决定因素。迄今为止，神经认知能力作为药物依从性差的一个危险因素，仅受到了很少的关注，但记忆和/或计划能力的显著损伤可能发挥了作用。我们研究了精神分裂症早期治疗计划中入院后早期药物依从性。
160 名 FEP 参与者和 35 名健康对照者完成了详尽的神经认知评估。根据 6 个月时的药物依从性，将 FEP 参与者分为依从性差（n=34）、部分依从性（n=27）和完全依从性（n=99）。研究了认知能力的特定领域和整体指标。
没有任何认知测量可以显著区分三种药物依从性组。
这些结果表明，在首发精神病中，神经认知能力与药物依从性之间没有很强的关联。
